---
document_datetime: 2025-07-25 11:07:13
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/volibris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: volibris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5810098
conversion_datetime: 2025-12-20 08:35:05.739981
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Volibris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 25/07/2025                          | N/A                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000285407                        | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP by removing the important identified risks of 'Decreased hemoglobin and hematocrit, including anemia requiring transfusion' and 'Testicular tubular atrophy / Male infertility' from the list of safety concerns, following the PRAC PSUR Assessment Report (EMEA/H/C/PSUSA/00000129/202306). In addition, the MAH took the opportunity implement editorial changes to update the clinical trial and post-authorisation exposure data; remove the reference to interim study results for AMB114588 following completion of the study; revise the objectives of the patient reminder card and remove the restriction to physicians providing the card; include updated information regarding existing treatment options for adults and pediatric patients; implement administrative changes aligning with the updated EU RMP template, including formatting adjustments   |            |     |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000277859 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 10/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| authorisation, including the risk management plan - C.I.11.a Implementation of wording agreed by the competent authority - Refused   |
|--------------------------------------------------------------------------------------------------------------------------------------|